Drug Profile
Research programme: CNS disorder therapeutics - QurAlis
Latest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator QurAlis Corporation
- Class Antidementias; Neuroprotectants
- Mechanism of Action AMPA receptor modulators; Dopamine D2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis; Dementia
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA
- 28 Dec 2022 No recent reports of development identified for preclinical development in Dementia in USA
- 19 Nov 2018 Preclinical trials in Amyotrophic lateral sclerosis in USA (unspecified route), prior to November 2018